Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas

Fumiaki Tanaka, Naotsugu Haraguchi, Kenji Isikawa, Hiroshi Inoue, Masaki Mori

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Dendritic cells (DCs) loaded with tumor antigens have been emerging as a new strategy in cancer treatment. The MAGE genes are selectively expressed in a variety of cancer tissues such as melanoma or gastrointestinal carcinomas. However, no expression is observed in normal tissues except testis. There are several reports on clinical trials with these immunogenic peptides including MAGE gene-derived, which were shown to be effective for some patients with carcinomas. We previously reported a clinical trial treating gastrointestinal carcinoma patients with immature DC and MAGE peptides via intravenous injection. Autologous DCs were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A02 or A24). In this study, patients were immunized with mature DCs pulsed with the MAGE-3 peptide four times every 2 weeks via s.c. injection close to the axilla and inguinal lymph nodes. Twenty-eight patients with advanced gastrointestinal carcinoma were treated and no toxic side effects were observed. Peptide-specific CTL responses, improvement in performance status, tumor marker decrease and minor tumor regressions after vaccination were observed in some patients. These results suggested that DC vaccination with the MAGE-3 peptide would be safe and can exhibit antitumor effects even in the patients with advanced gastrointestinal carcinoma who were previously treated with chemotherapy or radiation therapy.

Original languageEnglish
Pages (from-to)1111-1116
Number of pages6
JournalOncology reports
Volume20
Issue number5
DOIs
Publication statusPublished - Dec 1 2008

Fingerprint

Dendritic Cells
Vaccination
Carcinoma
Peptides
Clinical Trials
Neoplasms
Axilla
Groin
Poisons
Neoplasm Antigens
Tumor Biomarkers
varespladib methyl
Intravenous Injections
Haplotypes
Genes
Testis
Melanoma
Radiotherapy
Lymph Nodes
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. / Tanaka, Fumiaki; Haraguchi, Naotsugu; Isikawa, Kenji; Inoue, Hiroshi; Mori, Masaki.

In: Oncology reports, Vol. 20, No. 5, 01.12.2008, p. 1111-1116.

Research output: Contribution to journalArticle

Tanaka, Fumiaki ; Haraguchi, Naotsugu ; Isikawa, Kenji ; Inoue, Hiroshi ; Mori, Masaki. / Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. In: Oncology reports. 2008 ; Vol. 20, No. 5. pp. 1111-1116.
@article{dc0fada16d024045a018b435ab722fa1,
title = "Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas",
abstract = "Dendritic cells (DCs) loaded with tumor antigens have been emerging as a new strategy in cancer treatment. The MAGE genes are selectively expressed in a variety of cancer tissues such as melanoma or gastrointestinal carcinomas. However, no expression is observed in normal tissues except testis. There are several reports on clinical trials with these immunogenic peptides including MAGE gene-derived, which were shown to be effective for some patients with carcinomas. We previously reported a clinical trial treating gastrointestinal carcinoma patients with immature DC and MAGE peptides via intravenous injection. Autologous DCs were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A02 or A24). In this study, patients were immunized with mature DCs pulsed with the MAGE-3 peptide four times every 2 weeks via s.c. injection close to the axilla and inguinal lymph nodes. Twenty-eight patients with advanced gastrointestinal carcinoma were treated and no toxic side effects were observed. Peptide-specific CTL responses, improvement in performance status, tumor marker decrease and minor tumor regressions after vaccination were observed in some patients. These results suggested that DC vaccination with the MAGE-3 peptide would be safe and can exhibit antitumor effects even in the patients with advanced gastrointestinal carcinoma who were previously treated with chemotherapy or radiation therapy.",
author = "Fumiaki Tanaka and Naotsugu Haraguchi and Kenji Isikawa and Hiroshi Inoue and Masaki Mori",
year = "2008",
month = "12",
day = "1",
doi = "10.3892/or_00000117",
language = "English",
volume = "20",
pages = "1111--1116",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas

AU - Tanaka, Fumiaki

AU - Haraguchi, Naotsugu

AU - Isikawa, Kenji

AU - Inoue, Hiroshi

AU - Mori, Masaki

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Dendritic cells (DCs) loaded with tumor antigens have been emerging as a new strategy in cancer treatment. The MAGE genes are selectively expressed in a variety of cancer tissues such as melanoma or gastrointestinal carcinomas. However, no expression is observed in normal tissues except testis. There are several reports on clinical trials with these immunogenic peptides including MAGE gene-derived, which were shown to be effective for some patients with carcinomas. We previously reported a clinical trial treating gastrointestinal carcinoma patients with immature DC and MAGE peptides via intravenous injection. Autologous DCs were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A02 or A24). In this study, patients were immunized with mature DCs pulsed with the MAGE-3 peptide four times every 2 weeks via s.c. injection close to the axilla and inguinal lymph nodes. Twenty-eight patients with advanced gastrointestinal carcinoma were treated and no toxic side effects were observed. Peptide-specific CTL responses, improvement in performance status, tumor marker decrease and minor tumor regressions after vaccination were observed in some patients. These results suggested that DC vaccination with the MAGE-3 peptide would be safe and can exhibit antitumor effects even in the patients with advanced gastrointestinal carcinoma who were previously treated with chemotherapy or radiation therapy.

AB - Dendritic cells (DCs) loaded with tumor antigens have been emerging as a new strategy in cancer treatment. The MAGE genes are selectively expressed in a variety of cancer tissues such as melanoma or gastrointestinal carcinomas. However, no expression is observed in normal tissues except testis. There are several reports on clinical trials with these immunogenic peptides including MAGE gene-derived, which were shown to be effective for some patients with carcinomas. We previously reported a clinical trial treating gastrointestinal carcinoma patients with immature DC and MAGE peptides via intravenous injection. Autologous DCs were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A02 or A24). In this study, patients were immunized with mature DCs pulsed with the MAGE-3 peptide four times every 2 weeks via s.c. injection close to the axilla and inguinal lymph nodes. Twenty-eight patients with advanced gastrointestinal carcinoma were treated and no toxic side effects were observed. Peptide-specific CTL responses, improvement in performance status, tumor marker decrease and minor tumor regressions after vaccination were observed in some patients. These results suggested that DC vaccination with the MAGE-3 peptide would be safe and can exhibit antitumor effects even in the patients with advanced gastrointestinal carcinoma who were previously treated with chemotherapy or radiation therapy.

UR - http://www.scopus.com/inward/record.url?scp=58149352927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149352927&partnerID=8YFLogxK

U2 - 10.3892/or_00000117

DO - 10.3892/or_00000117

M3 - Article

C2 - 18949409

AN - SCOPUS:58149352927

VL - 20

SP - 1111

EP - 1116

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -